SCHEMBL10189176

SCHEMBL10189176

CCc1cc(-c2sncc2-c2ccc(C(F)(F)F)cc2)c(O)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPT P10636 1/20 0.38
CRHBP P24387 1/20 0.38
KMT2A Q03164 1/20 0.38
CRHR2 Q13324 1/20 0.38
SLC1A3 P43003 1/20 0.35
SLC1A2 P43004 1/20 0.35
SLC1A1 P43005 1/20 0.35
PTGS2 P35354 5/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
POLQ O75417 1/20 0.34
COMT P21964 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189171 0.87 PTGS2 (0.38) KDM4EMEN1HSP90AA1KMT2APTGS2
SCHEMBL619170 0.85 MEN1 (0.47) KDM4EMEN1MAPTKMT2APTGS2
SCHEMBL10189174 0.84 PTGS2 (0.37) MEN1HSP90AA1MAPTKMT2APTGS2
SCHEMBL10189167 0.84 PTGS2 (0.52) MEN1HSP90AA1MAPTKMT2APTGS2
SCHEMBL10188809 0.84 PTGS2 (0.37) MEN1HSP90AA1KMT2APTGS2
SCHEMBL10188872 0.82 PTGS2 (0.57) MEN1HSP90AA1MAPTKMT2APTGS2
SCHEMBL10188805 0.79 CCNC (0.38) HSP90AA1PTGS2POLQ
SCHEMBL12338740 0.78 MEN1 (0.54) KDM4EMEN1HSP90AA1MAPTCRHBP
SCHEMBL10189795 0.71 PIK3CA (0.36) KDM4EMEN1HSP90AA1MAPTCRHBP
SCHEMBL616208 0.71 MEN1 (0.47) KDM4EMEN1HSP90AA1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 KDM4E 2492/4885MEN1 1571/4885HSP90AA1 289/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 KDM4E 2492/4885MEN1 1571/4885HSP90AA1 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.